Securities and Exchange Commission v. Chan

CourtDistrict Court, D. Massachusetts
DecidedJune 8, 2020
Docket1:16-cv-11106
StatusUnknown

This text of Securities and Exchange Commission v. Chan (Securities and Exchange Commission v. Chan) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Securities and Exchange Commission v. Chan, (D. Mass. 2020).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

* SECURITIES AND EXCHANGE * COMMISSION, * * Plaintiff, * * v. * Civil Action No. 16-cv-11106-ADB * SCHULTZ CHAN (A/K/A JASON * CHAN), * * Defendant. * * *

MEMORANDUM AND ORDER ON PLAINTIFF’S MOTION FOR SUMMARY JUDGMENT

BURROUGHS, D.J. This SEC action arises out of a government investigation of an insider trading scheme involving publicly traded shares of the Massachusetts-based biopharmaceutical company Akebia Therapeutics, Inc. (“Akebia”). In a related criminal case, Defendant Schultz Chan (“Chan”), and his codefendant Songjiang Wang (“Wang”), were, inter alia, convicted of orchestrating an insider trading and tipping scheme that lasted from November 2013 to September 2015. Both the criminal and civil cases are based, at least in part, on Chan purchasing his employer’s stock and advising Wang to do the same while Chan was in possession of insider information concerning the results of Akebia’s clinical trials. [ECF No. 34 ¶ 11; ECF No. 35-2 ¶ 6; ECF No. 42-1 at 15]. Pending before the Court is the SEC’s motion for summary judgment. [ECF No. 32]. For the following reasons, the motion, [ECF No. 32], is GRANTED. I. BACKGROUND

A. Factual Background

The following facts are either uncontroverted pursuant to Federal Rule of Civil Procedure 56 and Local Rule 56.1, or stated in the light most favorable to the non-movant on each issue. On August 17, 2015, Chan was hired as Akebia’s Director of Biostatistics. [ECF No. 34 ¶ 18]. At that time, Wang was the Director of Statistical Programming at Merrimack Pharmaceuticals, Inc. (“Merrimack”). [Id. ¶ 9]. Akebia’s Insider Trading Policy mandated that “no employee was permitted to trade the company’s stock while in possession of material nonpublic information, and that no employee was permitted to disclose material nonpublic information to others who might buy or sell securities on the basis of that information.” [Id. ¶ 13]. Merrimack employed a similar policy. [ECF No. 34 ¶¶ 12–13]. Wang violated Merrimack’s policy when he shared Merrimack’s material nonpublic information with Chan, who then purchased Merrimack stock. [ECF No. 35-2 ¶ 24]. The Merrimack trades were charged in the criminal case, but not the civil one. Relevant to this civil action, Chan purchased nearly 14,000 shares of Akebia stock before the company announced in September 2015 that its drug candidate Vadadustat had achieved positive results in a clinical trial, [ECF No. 34 ¶¶ 15–16, 20–22], and instructed his wife1 and

1 The SEC asserts that Chan’s wife purchased over 23,000 shares of Akebia stock in her own name before the announcement, leading to approximately $115,000.00 in profits. [ECF No. 1 ¶¶ 25–30; ECF No. 1 ¶¶ 5, 38]. Because “Chan’s tipping of his wife was not one of the charges against him in the Criminal Case,” [ECF No. 33 at 11], and “it is not clear that the verdict rendered against Chan in the Criminal Case incorporated this misconduct,” the SEC “does not intend to pursue this portion of its claim if its Summary Judgment Motion is granted.” [ECF No. 33 at 18 n.8]. Accordingly, the Court need not address the allegations concerning Chan’s wife in ruling on the instant summary judgment motion. Wang2 to do the same, [id. ¶ 24]. Following this announcement, on September 8, 2015, the share price of Akebia’s stock increased by forty-five percent, [id. ¶ 14], resulting in a gain of approximately $68,699.00 for Chan.3,4 [Id. ¶¶ 14, 23]. The Government filed a criminal complaint against Chan and Wang in the District of

Massachusetts on June 13, 2016, based on their trading activity. [ECF No. 33 at 6]. On June 5, 2018, Chan was charged in a four-count second superseding indictment (“SSI”) with (1) conspiracy to commit securities fraud; (2) insider trading related to Chan’s trading in Merrimack securities; (3) insider trading related to Wang’s trading in Akebia securities; and (4) insider trading related to Chan’s trading in Akebia securities. [ECF No. 35-2 at 9–15]. On July 10, 2018, Chan was convicted on all four counts and sentenced to a term of thirty-six months’ imprisonment, a $65,000.00 fine, and restitution of $153,428.72. [Id.].5 The court in the criminal proceeding did not order the forfeiture of Chan’s profits.6 [Id. at 7]. Chan’s appeal of his conviction is currently pending. [Id.].

2 Wang purchased over 20,000 Akebia shares and 20 Akebia call options between August 28 and September 4, 2015. [ECF No. 34 ¶ 24].

3 Wang received approximately $108,011.00 in profits. [ECF No. 34 ¶ 24; ECF No. 33 at 18 n.8].

4 The SEC calculated Chan’s profits from his trading of Akebia’s securities by “calculat[ing] the difference between the price that [Chan] paid for his purchases of Akebia stock on August 19 and 21, 2015 prior to the Announcement, and the value of Akebia’s stock when the market closed on September 9, 2015 (i.e., the first trading day after the Announcement).” [ECF No. 35 ¶ 11].

5 Wang was indicted on and convicted of Counts One, Two, and Three. [ECF No. 33 at 6]. He was sentenced to a term of six months’ imprisonment, a $50,000.00 fine, and restitution of $17,047.64. [Id. at 6 n.3].

6 The Government has appealed this aspect of the trial court’s decision. [ECF No. 33 at 17 n.7]. B. Procedural History On June 14, 2016, one day after the Government filed its criminal complaint against Chan, the SEC filed the instant civil complaint (“the Complaint”). [ECF No. 1; ECF No. 33 at 6]. According to the SEC, the Complaint “is based on the same factual allegations” as Counts

Three and Four of the SSI. [Id.]. This Court stayed the civil proceeding during the pendency of the parallel criminal action. [ECF No. 10]. On June 13, 2019, following the resolution of the criminal case, the Court granted the SEC’s motion to lift the stay on the instant civil proceeding, [ECF No. 21], and the SEC filed its motion for summary judgment, which Chan opposed, [ECF No. 32; ECF No. 42]. II. LEGAL STANDARD

Summary judgment may be granted where the moving party shows “that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a). A fact is material where it “affect[s] the outcome of the suit under the governing law.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248 (1986). A genuine issue of material fact arises if “the evidence with respect to the material fact in dispute ‘is such that a reasonable jury could return a verdict for the nonmoving party.’” SEC v. Weed, 315 F. Supp. 3d 667, 673 (D. Mass. 2018) (quoting Anderson, 477 U.S. at 248). If the moving party demonstrates that there is no genuine dispute of material fact, the burden shifts to the non-moving party to “set forth specific facts showing that there is a genuine issue for trial.” Anderson, 477 U.S. at 250 (quoting Fed. R. Civ. P. 56(e)). The Court views “the record in the light most amiable to the nonmovants and indulge[s] all reasonable inferences favorable to them.” Garside v. Osco Drug, Inc., 895 F.2d 46, 48 (1st Cir. 1990). The granting of summary judgment is “appropriate if, after viewing the record in the non-moving party’s favor, the Court determines that no genuine issue of material fact exists and that the moving party is entitled to judgment as a matter of law.” Weed, 315 F. Supp. 3d at 673. III.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Huron Holding Corp. v. Lincoln Mine Operating Co.
312 U.S. 183 (Supreme Court, 1941)
Emich Motors Corp. v. General Motors Corp.
340 U.S. 558 (Supreme Court, 1951)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Weeks v. Angelone
528 U.S. 225 (Supreme Court, 2000)
Kane v. Town of Harpswell (In Re Kane)
254 F.3d 325 (First Circuit, 2001)
Securities & Exchange Commission v. Sargent
329 F.3d 34 (First Circuit, 2003)
Fleet National Bank v. Gray
375 F.3d 51 (First Circuit, 2004)
Securities & Exchange Commission v. Happ
392 F.3d 12 (First Circuit, 2004)
SEC v. Rocklage
470 F.3d 1 (First Circuit, 2006)
Ramallo Bros. Printing, Inc. v. El Día, Inc.
490 F.3d 86 (First Circuit, 2007)
Securities & Exchange Commission v. Ficken
546 F.3d 45 (First Circuit, 2008)
United States v. Bertram L. Podell
572 F.2d 31 (Second Circuit, 1978)
Joseph Gelb v. Royal Globe Insurance Company
798 F.2d 38 (Second Circuit, 1986)
Patriot Cinemas, Inc. v. General Cinema Corp.
834 F.2d 208 (First Circuit, 1987)
Milissa Garside v. Osco Drug, Inc.
895 F.2d 46 (First Circuit, 1990)
Joseph Lydon v. Boston Sand & Gravel Company
175 F.3d 6 (First Circuit, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
Securities and Exchange Commission v. Chan, Counsel Stack Legal Research, https://law.counselstack.com/opinion/securities-and-exchange-commission-v-chan-mad-2020.